Cambridge-based Sinaptica Therapeutics, a company providing electromagnetic treatment for patients with neurodegenerative diseases, announced its receipt of FDA Breakthrough Device Designation for its non-invasive SinaptiStim - AD System, designed to treat cognitive and functional decline in Alzheimer's patients.
SinaptiStim uses neurostimulation and brain wave monitoring technologies with an AI...
With a focus on epilepsy, California-based NeuroPace launched a new portal, called the nSight Platform. It's able to gather information about a patient's seizures and health progress outside of a hospital. According to the company, the goal is to help provide doctors with new data points to help personalize care.
The new online portal was designed to work in conjunction with the company’s...
NeuroPace, maker of an implanted neurostimulation therapy device for uncontrolled epileptic seizures, filed SEC documents yesterday outlining plans to raise as much as $75 million in an IPO listing on the Nasdaq.
The Mountain View, California-based company has been around since 1997 and has brought in a couple hundred million in funding across several rounds, according to CrunchBase. In fact, the...
NeuroPace, the maker of an implanted neurostimulation therapy device for uncontrolled epileptic seizures, announced a $33 million equity raise on Monday. Accelmed Partners led the investment, which was joined by new backers such as Revelation Partners, Soleus Capital and an unnamed strategic investor. Prior backers KCK Group and OrbiMed Advisors also contributed.
Alongside the equity, NeuroPace...
